The Fundamental Place of Pap Test in Iran, Does Primary HPV‑Genotyping Seem Cost‑Effective in Replace? A Cohort Study

Azam Zafarbakhsh, Fariba Behnamfar, Matin Shariati, Atefeh Vaezi, Leila Mousavi Seresht

Abstract


Background: Human papillomavirus (HPV) is a known risk factor for cervical cancer, and currently, primary HPV typing is recommended for screening instead of cervical cytology. However, there are limited studies on the prevalence of HPV in Iran. Methods: This cross‑sectional study evaluated the liquid‑based cervical smears of 700 women with no history of HPV vaccination and cervical dysplastic disease from 2017 to 2020 in Isfahan, Iran. Here, we compare the prevalence of HPV genotypes using COBAS with Pap smear cytology results in evaluating the most appropriate cervical cancer screening test. Results: The prevalence of HPV infection was 23.3%, including 8.7% with HPV 16/18 and 14.6% with other HR (high‑risk) HPVs. In cytology reports, 8 out of 16 individuals with high‑risk lesions were negative for any type of HPV; on the other hand, there were 129 HR HPV‑positive patients out of 570 negative or low‑risk Pap smear results. Conclusions: It assumed that there is no superiority for HPV genotyping over cytology or vice versa in detecting high‑risk patients for cervical cancer; as only 26.8% of women with HPV show abnormal cytology; and from those with normal cytology, 17.9% were positive for HR HPV.

International Journal of Preventive Medicine 16():21, April 2025. | DOI: 10.4103/ijpvm.ijpvm_283_23

Corresponding Author: Dr. Leila Mousavi Seresht

E‑mail:lmousavi.lm@gmail.com

You can also search for this author in: PubMed Google Scholar


Keywords


Human papillomavirus viruses; mass screening; Pap smear; uterine cervical neoplasms

Full Text:

PDF

References


Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144:1941–53.

Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol 2009;20:556–63.

Khodakarami N, Farzaneh F, Yavari P, Akbari ME. Cervical cancer screening: Recommendations for muslim societies. Asian Pacific J Cancer Prev 2016;17:239–47.

Akbari A, Khayamzadeh M, Salmanian R, Moradi A, Akbari ME. Epidemiology and survival of cervical cancer in Iran based on national cancer registry data (2008 2014). Front Oncol 2023;13:1 7.

Refaei M, Nayeri ND, Khakbazan Z, Pakgohar M. Cervical cancer screening in Iranian women: Healthcare practitioner perceptions and views. Asian Pacific J Cancer Prev 2017;18:357 63.

Fakhrolmobasheri M, Seresht LM. Cost Effectiveness of HPV vaccination; Need for Economic and Social Policy Intervention. Arch Iran Med 2022;25:343 6.

Rostami S, Nahvijou A. Gynecologic Cancers Estimates in the I.R. Iran, 2012 2040. Basic Clin Cancer Res 2022;13:111–8.

Hasanzadeh M, Rejali M, Mehramiz M, Akbari M, Mousavi Seresht L, Yazdandoost Y, et al. The interaction of high and low risk human papillomavirus genotypes increases the risk of developing genital warts: A population based cohort study. J Cell Biochem 2019;120:12870–4.

Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis 2014;41:660.

Cancer Tomorrow. Available from: https://gco.iarc.fr/tomorrow/ en/dataviz/bubbles?types=0&sexes=0&mode=population&gro up_populations=0&multiple_populations=1&multiple_cancers= 1&cancers=39&populations=903_904_905_908_909_935&apc =cat_ca20v1.5_ca23v 1.5&group_cancers=1. [Last accessed on 2023 Jul 30].

Shah SC, Kayamba V, Peek RM, Heimburger D. Cancer control in low and middle income countries: Is it time to consider screening? J Glob Oncol 2019;5:1 8.

Yaghoubi M, Nojomi M, Vaezi A, Erfani V, Mahmoudi S, Ezoji K, et al. Cost effectiveness analysis of the introduction of HPV vaccination of 9 year old girls in Iran. Value Heal Reg Issues 2018;15:112–9.

Drolet M, Laprise J F, Martin D, Jit M, Bénard É, Gingras G, et al. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low income and middle income countries in the context of limited resources: A mathematical modelling analysis. Lancet Infect Dis 2021;21:1598 610.

Emami RSH, Aghajani H, Haghazali M, Nadali F, Ramazani F, Dabiri E, et al. The most common cancers in Iranian women. Iran J Publ Health 2009;38(Suppl 1):109 12.

Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Annals of Oncology. Available from: https://www.annalsofoncology. org/ article/S0923 7534(19)41382-3/fulltext. [Last accessed on 2021 Jul 26].

Danaei M, Haghdoost A, Momeni M. An epidemiological review of common cancers in Iran; A review article. Iran J Blood Cancer 2019;11:77–84.

Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP risk based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2020;24:102–31.

Stenger M. Cobas HPV test for first line screening for cervical cancer. J Community Support Oncol 2014;12:156–7.

Wright TC, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: Design, methods, and baseline results. Am J Obstet Gynecol 2012;206:46.e1 11.

Sun H, Masand RP, Patel SJ, Padmanabhan V. High grade squamous intraepithelial lesion on high risk HPV negative patients: Why we still need the Pap test. Diagn Cytopathol 2018;46:908–13.

Loopik DL, IntHout J, Ebisch RMF, Melchers WJG, Massuger LFAG, Siebers AG, et al. The risk of cervical cancer after cervical intraepithelial neoplasia grade 3: A population based cohort study with 80,442 women. Gynecol Oncol 2020;157:195–201.

Muderris T, Afsar I, Yıldız A, Varer CA. HPV genotype distribution among women with normal and abnormal cervical cytology in Turkey. Rev Esp Quimioter 2019;32:516.

Su Y, Yuan Z, Xu C, Li Z, Zhu R, Zhang W, et al. Prevalence and genotype distribution of human papillomavirus infection among women: A population based study in Dali Bai Autonomous Prefecture, Yunnan Province, China. J Med Virol 2019;91:1553–61.

Kovacevic GI, Milosevic V, Nikolic N, Patic A, Dopudj N, Radovanov J, et al. The prevalence of 30 HPV genotypes detected by EUROArray HPV in cervical samples among unvaccinated women from Vojvodina province, Serbia PLoS One 2021;16:e0249134.

Meloni A, Pilia R, Campagna M, Usai A, Masia G, Caredda V, et al. Prevalence and molecular epidemiology of human papillomavirus infection in italian women with cervical cytological abnormalities. J Public health Res 2014;3:157.

Dasari P, Rajathi S, Kumar SV. Colposcopic evaluation of cervix with persistent inflammatory Pap smear: A prospective analytical study. Cytojournal 2010;7:16.

Jamdar F, Farzaneh F, Navidpour F, Younesi S, Balvayeh P, Hosseini M, et al. Prevalence of human papillomavirus infection among Iranian women using COBAS HPV DNA testing. Infect Agent Cancer 2018;13:6.

Haghshenas M, Golini Moghaddam T, Rafiei A, Emadeian O, Shykhpour A, Ashrafi GH. Prevalence and type distribution of high risk human papillomavirus in patients with cervical cancer: A population based study. Infect Agent Cancer 2013;8:20.

Ahmadi S, Goudarzi H, Jalilvand A, Esmaeilzadeh A. Human papilloma virus genotype distribution in cervical lesions in Zanjan, Iran. Asian Pacific J Cancer Prev APJCP 2017;18:3373 7.

Pouryasin M, Sharafi H, Mousavi AS, Khodadad S, Marjani M, Jamshidi F, et al. Distribution of human Papillomavirus genotypes in liquid based samples; abundance of HPV 53 in Tehran, Iran. Iran J Public Health 2014;43:1159–60.